Use of pharmacoeconomics in prescribing research. Part 1: Costs - Moving beyond the acquisition price for drugs

Journal of Clinical Pharmacy and Therapeutics

Volumn 28, Issue 1, 2003, Pages 73-79

  Robertson, Jane ^a,b   Lang, D ^a   Hill, S ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b NEWCASTLE MATER HOSPITAL   (Australia)

Author keywords

Economic evaluation; Pharmacoeconomics

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG MONITORING; DRUG RESEARCH; ECONOMIC ASPECT; ECONOMIC EVALUATION; HOSPITAL PHARMACY; INFORMATION PROCESSING; INSURANCE; PRESCRIPTION; PURCHASING; SENSITIVITY ANALYSIS;

COST CONTROL; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG UTILIZATION REVIEW; ECONOMICS, PHARMACEUTICAL; HUMANS; PHARMACEUTICAL PREPARATIONS; PRESCRIPTIONS, DRUG; RESEARCH DESIGN;

EID: 0037293222     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2003.00452.x     Document Type: Article

References (24)

1. Hill SR, Mitchell AS, Henry DA. (2000) Problems with the interpretation of pharmacoeconomic analyses. A review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA, 283, 2116-2121.
2. Larson LN. (1996) Cost determination and analysis. In: Bootman JL, Townsend RJ, McGhan WF, eds. Principles of pharmacoeconomics, 2nd edn, Cincinnati: Harvey Whitney Books.
3. Palmer S, Raftery J. (1999) Opportunity costs. BMJ, 318, 1551-1552.
4. Meltzer MI. (2001) Introduction to health economics for physicians. Lancet, 358, 993-998.
5. Department of Health and Aged Care. (2002) Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including major submissions involving economic analyses. Available at http://www.health.gov.au/pbs/pubs/pharmpac/gusubpac.htm (Accessed 9th May 2002).
6. National Institute for Clinical Excellence. (2001) Guidance for manufacturers and sponsors. Available at http://www.nice.org.uk/pdf/technicalguidanceformanufacturersandsponsors.pdf (Accessed 9th May 2002).
7. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. (1997) Basic types of economic evaluation. In: Methods for the economic evaluation of health care programmes, 2nd edn, New York: Oxford University Press.
8. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. (1997) Cost-effectiveness analysis. In: Methods for the economic evaluation of health care programmes, 2nd edn, New York: Oxford University Press.
9. Sculpher M. (2001) The role and estimation of productivity costs in economic evaluation. In: Drummond M, McGuire A, eds. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press.
10. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. (1997) Cost analysis. In: Methods for the economic evaluation of health care programmes, 2nd edn, New York: Oxford University Press.
11. Harris A, Crowley S, Defina J, Hawthorne G. (1997) Checklist for the design and protocols to collect economic information alongside clinical trials in Australia. Centre for Health Program Evaluation, Working Paper 51.
12. Nuitjen MJC, Engelfreit P, Duijn K, Bruijn G, Wierz D, Koopmanschap M. (2001) A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics, 19, 1051-1064.
13. O'Brien B. (1996) Economic evaluation of pharmaceuticals. Frankenstein's monster or vampire of trials? Medical Care, 34, DS99-DS108.
14. Schulman KA, Glick H, Polsky D, Eisenberg JM. (2000) Pharmacoeconomics' economic evaluation of pharmaceuticals. In: Strom BL, ed. Pharmacoepidemiology, 3rd edn, New York: John Wiley & Sons Ltd.
15. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. (1997) Collection and analysis of data. In: Methods for the economic evaluation of health care programmes, 2nd edn, New York: Oxford University Press.
16. Raftery J. (2000) Costing in economic evaluation. BMJ, 320, 1597.
17. Development of AN-DRG v3.1 and AR-DRG v4.0 cost weights. (2002) Available at http://www.health.gov.au/casemix/costing/costw1.htm (Accessed 9th May 2002).
18. Medicare Benefits Schedule (MBS). (2002) Canberra: Commonwealth Department of Health and Ageing, May 2002. Available at http://www.health.gov.au:80/pubs/mbs (Accessed 5th June 2002).
19. Schedule of Pharmaceutical Benefits for Approved Pharmacists and Medical Practitioners. (2002) Canberra: Commonwealth Department of Health and Ageing, May 2002. Available at http://www1.health.gov.au/pbs (Accessed 5th June 2002).
20. Briggs A. (1999) Handling uncertainty in economic evaluation. BMJ, 319, 120.
21. Torgerson DJ, Raftery J. (1999) Discounting. BMJ, 319, 914-915.
22. Drummond MF, Jefferson TO, on behalf of the BMJ Economic Evaluation Working Party. (1996) Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ, 313, 275-283.
23. Anonymous (1995) Task force on principles for economic analysis of health care technology. Economic analysis of heath care technology. Annals of Internal Medicine, 122, 61-70.
24. Siegel JE, Weinstein MC, Torrance GW. (1996) Reporting cost-effectiveness studies and results. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in health and medicine. New York: Oxford University Press.